Sun et al. in their study observed that among 484 advanced NSCLC patients, 38% had EGFR mutation, whereas 8% had KRAS and only two patients had both KRAS and EGFR mutations (co-mutation of KRAS/EGFR were G12V/deletion in exon nine and G12D/L858R) [159]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.